@article{oai:repo.qst.go.jp:00086172,
 author = {Nakano, Yoshikazu and Shimada, Hitoshi and Shinotoh, Hitoshi and Hirano, Shigeki and Tagai, Kenji and Sano, Yasunori and Yamamoto, Yasuharu and Endo, Hironobu and Matsuoka, Kiwamu and Takahata, Keisuke and Kubota, Manabu and Takado, Yuhei and Kimura, Yasuyuki and Ichise, Masanori and Ono, Maiko and Sahara, Naruhiko and Kawamura, Kazunori and Ming-Rong, Zhang and Kuwabara, Satoshi and Suhara, Tetsuya and Higuchi, Makoto and Yoshikazu, Nakano and Hitoshi, Shimada and Hitoshi, Shinoto and Shigeki, Hirano and Kenji, Tagai and Yasunori, Sano and Yamamoto, Yasuharu and Hironobu, Endo and Kiwamu, Matsuoka and Keisuke, Takahata and Manabu, Kubota and Yuhei, Takado and Yasuyuki, Kimura and Masanori, Ichise and Maiko, Ono and Naruhiko, Sahara and Kazunori, Kawamura and Zhang, Ming-Rong and Tetsuya, Suhara and Makoto, Higuchi},
 issue = {1},
 journal = {Parkinsonism & related disorders},
 month = {Jan},
 note = {Corticobasal degeneration (CBD) is the most common neuropathological substrate for clinically diagnosed corticobasal syndrome (CBS), while identifying CBD pathology in living individuals has been challenging. This study aimed to examine the capability of positron emission tomography (PET) to detect CBD-type tau depositions and neuropathological classification of CBS.},
 pages = {92--98},
 title = {PET-based classification of corticobasal syndrome.},
 volume = {98},
 year = {2022}
}